Development of novel Positron Emission Tomography (PET) radiotracers to study the biological processes that are characteristic of tumour cells.
Development, validation and/or qualification of existing PET radiotracers so that they can be used as predictive, prognostic, pharmacological and/or surrogate response biomarkers in oncology patients.
Current Research
Current projects involve tracers to study cell proliferation, hypoxia and angiogenesis.
Collaborations
Prof Fiona Gilbert, University of Cambridge
Prof Paula Ghaneh, University of Liverpool
Prof David O'Hagan, University of St Andrews
Kemotech, Italy
Funding and Grants
Current Grants:
Validation of FLT-PET as a predictive biomarker in breast cancer (Cancer Research UK)
18F-fluoroazomycin-arabinofuranoside (FAZA) as a PET tracer in the detection of tumour hypoxia in patients with colorectal carcinoma: A pilot study (NHS Grampian Endowment)
Detection of hypoxia in breast cancer with Fluoroazomycin arabinoside (FAZA) analogues (Breast Cancer Campaign)
Studying the effect of different hypoxic subtypes on anti-cancer therapeutics in breast cancer cells (NHS Grampian Endowment)
Developing a novel αvβ3 radiotracer to report on tumour angiogenesis (Knowledge Exchange Transfer Fund)
Development of 18F-labelled PET tracer for preclinical HER2 imaging of gastroesophageal adenocarcinomas (NHS Grampian Endowment)
Inositol phospholipids regulate the guanine-nucleotide-exchange factor Tiam1 by facilitating its binding to the plasma membrane and regulating GDP/GTP exchange on Rac1
Fleming, I. N., Batty, I. H., Prescott, A. R., Gray, A., Kular, G. S., Stewart, H., Downes, C. P.
